These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19423470)

  • 1. Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study).
    Weiss G; Reimnitz P; Hampel B; Muehlhofer E; Lippert H;
    J Chemother; 2009 Apr; 21(2):170-80. PubMed ID: 19423470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
    Solomkin J; Zhao YP; Ma EL; Chen MJ; Hampel B;
    Int J Antimicrob Agents; 2009 Nov; 34(5):439-45. PubMed ID: 19692210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections.
    Malangoni MA; Song J; Herrington J; Choudhri S; Pertel P
    Ann Surg; 2006 Aug; 244(2):204-11. PubMed ID: 16858182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection.
    Giordano P; Song J; Pertel P; Herrington J; Kowalsky S
    Int J Antimicrob Agents; 2005 Nov; 26(5):357-65. PubMed ID: 16229991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections.
    Towfigh S; Pasternak J; Poirier A; Leister H; Babinchak T
    Clin Microbiol Infect; 2010 Aug; 16(8):1274-81. PubMed ID: 20670293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.
    Gyssens IC; Dryden M; Kujath P; Nathwani D; Schaper N; Hampel B; Reimnitz P; Alder J; Arvis P
    J Antimicrob Chemother; 2011 Nov; 66(11):2632-42. PubMed ID: 21896561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.
    Ross JD; Cronjé HS; Paszkowski T; Rakoczi I; Vildaite D; Kureishi A; Alefelder M; Arvis P; Reimnitz P;
    Sex Transm Infect; 2006 Dec; 82(6):446-51. PubMed ID: 16723364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.
    Vick-Fragoso R; Hernández-Oliva G; Cruz-Alcázar J; Amábile-Cuevas CF; Arvis P; Reimnitz P; Bogner JR;
    Infection; 2009 Oct; 37(5):407-17. PubMed ID: 19768381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience.
    Rakkar S; Roberts K; Towe BF; Flores SM; Heyd A; Warner J
    Int J Clin Pract; 2001 Jun; 55(5):309-15. PubMed ID: 11452678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
    Finch R; Schürmann D; Collins O; Kubin R; McGivern J; Bobbaers H; Izquierdo JL; Nikolaides P; Ogundare F; Raz R; Zuck P; Hoeffken G
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1746-54. PubMed ID: 12019085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
    Lipsky BA; Giordano P; Choudhri S; Song J
    J Antimicrob Chemother; 2007 Aug; 60(2):370-6. PubMed ID: 17553812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a prospective, randomized, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous/oral)+metronidazole (intravenous/oral) with ceftriaxone (intravenous)+metronidazole (intravenous/oral) for the treatment of intra-abdominal infections.
    Starakis I; Karravias D; Asimakopoulos C; Kolaras P; Nikolaidis P; Harlaftis N; Skoutelis A; Bassaris H
    Int J Antimicrob Agents; 2003 Jan; 21(1):49-57. PubMed ID: 12507837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors.
    Portier H; Brambilla C; Garre M; Paganin F; Poubeau P; Zuck P
    Eur J Clin Microbiol Infect Dis; 2005 Jun; 24(6):367-76. PubMed ID: 15944847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.
    Katz E; Larsen LS; Fogarty CM; Hamed K; Song J; Choudhri S
    J Emerg Med; 2004 Nov; 27(4):395-405. PubMed ID: 15498622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia.
    Höffken G; Barth J; Rubinstein E; Beckmann H;
    Infection; 2007 Dec; 35(6):414-20. PubMed ID: 18034211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial.
    Aşicioğlu O; Gungorduk K; Ozdemir A; Ertas IE; Yildirim G; Sanci M; Ark C
    Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):116-21. PubMed ID: 23993130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of sequential intravenous/oral ciprofloxacin plus metronidazole with intravenous ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections.
    Wacha H; Warren B; Bassaris H; Nikolaidis P;
    Surg Infect (Larchmt); 2006 Aug; 7(4):341-54. PubMed ID: 16978077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults.
    Yellin AE; Hassett JM; Fernandez A; Geib J; Adeyi B; Woods GL; Teppler H;
    Int J Antimicrob Agents; 2002 Sep; 20(3):165-73. PubMed ID: 12385694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis.
    Ferguson BJ; Guzzetta RV; Spector SL; Hadley JA
    Otolaryngol Head Neck Surg; 2004 Sep; 131(3):207-14. PubMed ID: 15365537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.